• Ginsenoside Rg1: Mechanistic Leverage in Translational Neuro

  2026-04-23

  This thought-leadership article explores how Ginsenoside Rg1, a Panax-derived triterpene saponin, is redefining the landscape of translational neuroprotection research. By unpacking mechanistic insights, recent experimental evidence, and protocol guidance, this piece offers strategic direction for researchers targeting neuroimmune disruption, apoptosis, and inflammation. The article also positions APExBIO's Ginsenoside Rg1 as a benchmark tool for rigorous, next-generation studies, while building on and advancing the discourse found in prior resources.

• Pharmacokinetics of Temafloxacin: Implications for Antibacte

  2026-04-22

  This review synthesizes the pharmacokinetic properties of Temafloxacin, a fluoroquinolone broad-spectrum antibacterial agent, as detailed in Dudley (1991). The study highlights Temafloxacin's high oral bioavailability, favorable tissue distribution, and practical dosing schedule, providing a robust foundation for its application in laboratory infection models and antibacterial agent validation.

• Demethyleneberberine as a Multi-Pathway Modulator in Hunting

  2026-04-22

  This article reviews the hypothesis-driven study exploring Demethyleneberberine (DMB) as a potential therapeutic for Huntington’s disease. The analysis focuses on DMB’s unique multi-pathway inhibition of oxidative stress and neuroinflammation, highlighting its mechanistic relevance and implications for neurodegenerative disease research.

• Renin–Angiotensin System Modulation of SARS-CoV-2 Entry via

  2026-04-21

  This study investigates how peptides of the renin–angiotensin system (RAS) differentially regulate SARS-CoV-2 entry through the ACE2 receptor. Notably, angiotensin IV—but not angiotensin II—was found to modulate viral infectivity, revealing a previously unrecognized connection between cardiovascular hormonal pathways and COVID-19 pathogenesis.

• QRICH1 Drives HBV-Induced HMGB1 Secretion and Hepatic Fibros

  2026-04-21

  This study demonstrates that QRICH1 amplifies HBV-driven HMGB1 translocation and secretion in hepatocytes by modulating its transcription, thereby exacerbating hepatic fibrosis. The findings provide mechanistic insight into the interplay between ER stress, QRICH1, and the HBV-induced inflammatory response, with implications for liver disease research and potential intervention strategies.

• Berbamine Hydrochloride: Applied NF-κB Activity Inhibitor Wo

  2026-04-20

  Berbamine hydrochloride provides robust, reproducible NF-κB signaling pathway inhibition and anticancer activity across leukemia and hepatocellular carcinoma models. This article delivers protocol-driven guidance, advanced troubleshooting, and real-world workflow enhancements for maximizing its impact in cancer research.

• DiscoveryProbe Protease Inhibitor Library: Advanced HTS Appl

  2026-04-20

  The DiscoveryProbe™ Protease Inhibitor Library empowers high-throughput and high-content screening with 825 validated, cell-permeable inhibitors. Its robust, automation-ready design accelerates apoptosis, cancer, and infectious disease research, enabling reproducible modulation of protease activity across mechanistic and translational workflows.

• Refining In Vitro Evaluation of PARP Inhibitors in Cancer Re

  2026-04-19

  Schwartz’s dissertation critically addresses how conventional in vitro assays may misrepresent anti-cancer drug efficacy by conflating growth arrest with cell death. This methodological advance informs translational researchers developing novel PARP inhibitors, such as AZD2461, with more precise metrics for assessing drug responses and resistance mechanisms.

• Optimizing Mouse Corneal Epithelial Cell Expansion with 6C M

  2026-04-18

  This study introduces a novel serum-free 6C medium that prolongs the proliferative activity of mouse corneal epithelial cells (mCEC) in vitro and in vivo. By strategically incorporating multiple pathway inhibitors, including LDN-193189, the protocol enables robust mCEC expansion and preserves progenitor characteristics, supporting advances in regenerative ophthalmology.

• Targeting Glutamine Metabolism in Hepatic Stellate Cells to

  2026-04-17

  The reference study uncovers how inhibition of glutamine metabolism in hepatic stellate cells (HSCs) via modulation of SIRT4 and GDH leads to attenuation of liver fibrosis. These findings offer mechanistic insights and highlight new therapeutic research avenues targeting mitochondrial and metabolic pathways in chronic liver disease.

• Angiotensin 1/2 (5-7): Reliable Peptide for RAS & Viral Assa

  2026-04-16

  This article provides an evidence-backed guide for biomedical researchers seeking reproducibility in cell viability and signaling assays using Angiotensin 1/2 (5-7) (SKU A1049). It addresses practical laboratory scenarios, protocol optimization, and product selection, highlighting the peptide's documented purity, solubility, and relevance in both cardiovascular and viral pathogenesis research.

• Nanoparticle-Mediated PTEN mRNA Delivery Reverses Trastuzuma

  2026-04-15

  This paper presents a nanoparticle-based system for systemic delivery of in vitro transcribed PTEN mRNA, enabling restoration of tumor suppressor function and effective reversal of trastuzumab resistance in HER2-positive breast cancer. The findings provide a mechanistic and translational blueprint for targeting PI3K/Akt pathway reactivation in resistant tumor contexts.

• TRPV1+ Nerve Stimulation Suppresses Inflammation via Reflex

  2026-04-14

  This study demonstrates that stimulation of TRPV1-positive peripheral nerves at specific skin regions initiates a somato-autonomic reflex, reducing systemic inflammation through catecholamine release and gene modulation in the spleen. The findings clarify the neural circuitry underlying neuroimmune control and underscore the translational potential for targeted TRPV1 agonists in inflammation research.

• Valemetostat (DS-3201): Selective Dual EZH1/2 Inhibitor for

  2026-04-13

  Valemetostat (DS-3201) is a first-in-class, highly selective inhibitor of EZH1 and EZH2, designed for epigenetic cancer therapy. It demonstrates nanomolar potency against wild-type and mutant EZH2 and is clinically effective in relapsed or refractory follicular lymphoma. Supplied by APExBIO, Valemetostat is optimized for rigorous research workflows, with well-documented specificity and safety.

• KX2-391 Dihydrochloride: Applied Workflows in Oncology and N

  2026-04-13

  KX2-391 dihydrochloride stands out as a dual-action inhibitor, enabling advanced research in cancer, virology, and botulinum neurotoxin A (BoNT/A) studies. This article delivers protocol-driven guidance, experimental troubleshooting, and translational insights for maximizing reproducibility and efficacy with this well-characterized compound.

405 records 1/27 page Next 12345 下5页 Last page